Study: Sputnik V nasal vaccine forms long-lasting and stable immunity to coronavirus

NICEM them.

N.F.

Gamaleya and the Russian Direct Investment Fund (RDIF) announced that an article with the results of a study on the use of the nasal form of the COVID-19 vaccine Sputnik V has been published in the peer-reviewed international medical journal Emerging Microbes & Infections.

“According to data obtained in the framework of studies on laboratory animals, the nasal form of Sputnik V forms a long-lasting and stable immune response,” the RDIF said.

The article has passed the peer review process.

It is available via the link. 

The nasal form of the vaccine was studied in mice and marmoset monkeys. 

“The high immunogenic properties of the vaccine were confirmed by the pronounced formation of IgG

neutralizing antibodies in the blood serum, the rapid growth of antigen-specific T cells and the formation of IgA

in the nasal mucosa,” the RDIF said.

It is noted that the vaccine formed a strong and long-lasting immune response lasting at least 180 days against coronavirus at the level of both the whole organism and locally on the respiratory mucosa of animals.

Previously Director of the Center

Gamalei Alexander Gintsburg said that the nasal vaccine against coronavirus in experimental experiments proved to be effective against the omicron strain.